Search the GHTC website

Global health R&D delivers for Nevada

US government investment in global health R&D has delivered

Amount
$3.7 million
to Nevada research institutions
Nevada's top USG-funded global health R&D institutions

Nevada's top USG-funded global health R&D institutions

University of Nevada, Las Vegas
$3.2 million
University of Nevada, Reno
$487 thousand

Nevada's top areas of global health R&D by USG funding

25%
COVID-19
70.2%
Diarrheal diseases
4.3%
Neglected tropical diseases
Helminth infections (Worms & Flukes)
0.5%
Salmonella infections
Global health R&D at work in Nevada

A team of scientists from the University of Nevada conducted research uncovering how the bacteria Shigella causes shigellosis, a diarrheal disease that kills more than 1 million people each year. When Shigella bacteria invade a human host, environmental conditions stimulate a process within the bacteria that allows them to thrive. Central to this transformation are two proteins that work together to increase the bacteria’s harmfulness. The team found that the production of one of the proteins can be controlled separately from the other, a discovery that could lead to new treatments. Researchers are continuing to study how these proteins function, intending to identify new targets for drug development. For large numbers of people living in low-income countries, improved antibiotics could mean the difference between life and death. No vaccine currently exists for Shigella.

Footnotes
  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: PATH/Patrick McKern